PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S.

Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic ...

The CDC was expected last month to publish a study showing that Covid vaccines reduced the likelihood of severe illness, but ...

SkinJect™ , a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome , a rare autosomal dominant disease ...

Oyster reefs aren’t random piles—they’re carefully shaped survival systems. Researchers discovered that certain geometric ...

This reduces delays and improves results. For example, some platforms offer support for early-stage research and help teams ...

Revision Skincare(R), a physician--dispensed medical--grade skincare company focused on clinically validated innovation, today announced the publication of two peer--reviewed clinical studies in the ...

Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced a poster ...

Medicus Pharma Ltd. MDCX said Monday it has submitted an optimized Phase 2 study design to the U.S. Food and Drug ...

UAB is leading a national study examining how personalized genetic risk information can improve prevention of chronic ...